Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
How Alloy is Enabling the Discovery and Engineering of Chimeric Antigen Receptors for Cell Therapies
Alloy Therapeutics enables high-throughput CAR discovery and engineering by providing diverse binder sets from its ATX-Gx™ and ATX-SiD platforms to optimize antigen specificity and affinity. Their Discovery Services offer comprehensive functional screening in primary immune cells—including expression, activation, and cell-killing assays—to streamline the development of next-generation CAR-T, NK, and macrophage therapies. Cell therapy utilizing chimeric […]
How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Alloy Therapeutics is democratizing access to foundational drug delivery, formulation, and half-life extension technologies to overcome critical barriers such as molecular stability and crossing the blood-brain barrier. Through its Innovation Subscription model and collaborations with institutions like MIT’s Marble Center, Alloy provides the drug discovery community with validated, pre-competitive delivery platforms including LNPs and antibody-drug […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Alloy Will Help the Drug Discovery Community Unlock the Therapeutic Potential of ASOs
Alloy Therapeutics is expanding into genetic medicines with its ASO Discovery Services group, offering democratized access to novel chemistries, bioinformatics-driven design, and ASO-antibody conjugates. Led by industry pioneers Dr. Sudhir Agrawal and Dr. Ben Chih, this initiative aims to overcome historical toxicity and accessibility barriers to unlock the full therapeutic potential of antisense oligonucleotides. Our […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]
Partnering with Target-Rich Biotech Companies
Alloy Therapeutics collaborates with “target-rich” biotech companies through its 82VS venture studio to launch asset-centric joint ventures that accelerate drug discovery. By providing end-to-end Discovery Services and company creation support, Alloy enables partners to produce high-value targets and move promising treatments toward the clinic without traditional capital constraints. Running a successful early-stage biotech company requires […]
Democratizing Access for Academic Entrepreneurs
We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease. An exciting element of this dynamic is how under-resourced, smaller teams […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Alloy Therapeutics led a $7 million Series A for Mytide Therapeutics to scale its AI-enabled Gen2 platform, which uses machine learning to accelerate peptide manufacturing by 30x. This technology enables the rapid, high-purity production of complex natural and non-natural peptides for therapeutic discovery and personalized peptide vaccines (PPV). Biotech ecosystem company Alloy Therapeutics leads the […]
Celebrating 100 Partners in the Alloy Biotechnology Ecosystem
Alloy Therapeutics celebrates reaching 100 partners within its global biotechnology ecosystem, a collaborative network designed to democratize access to foundational drug discovery technologies. This diverse community includes academic labs, biotechs, and large pharma companies leveraging shared resources and humanized mouse platforms to accelerate therapeutic development. At Alloy we refer to ourselves as a biotechnology ecosystem […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
Alloy Therapeutics has enhanced its antibody discovery ecosystem by acquiring deepCDR Biologics, integrating advanced bioinformatics and deep learning capabilities into Alloy Discovery Services. This acquisition enables the rapid identification of high-affinity antibody candidates through machine learning-guided protein engineering and proprietary mammalian display technologies. The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery […]